Genfit Delays NASH Data While It Confers With US FDA On Methodology

 
• By Joseph Haas
Data Collection - Three Arrows Hit in Red Target
Genfit will await FDA insight on statistical methodology before unblinding its Phase III NASH study

More from Clinical Trials

More from R&D